Busulfex busulfan: Phase II; marketed for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell t

Orphan Medical Inc. (ORPH), Minneapolis, Minn. Product: Busulfex busulfan Business: Cancer Therapeutic category: Adjunct, Cytotoxic Target: DNA Description: Intravenous busulfan Indication: Treat non...